RBC Capital analyst Brian Abrahams highlighted that clinicaltrials.gov listed one of Celgene (NASDAQ: CELG) partnered early-stage pipeline drugs, anti-CD47 antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE